Evolution of Blood Safety in Switzerland over the Last 25 Years for HIV, HCV, HBV and Treponema pallidum

Niederhauser, Christoph; Tinguely, Caroline; Stolz, Martin; Vock, Michael; Dusouqui, Soraya Amar El; Gowland, Peter

doi:10.3390/v14122611

Cited by 9 publications

(11 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our survey reports updated data on global blood donation NAT screening. We observed increased adoption of NAT for transfusiontransmitted viruses over the past decade, with an increase in HIV, HCV previously in countries that do not perform anti-HBc testing [19]. Without NAT, these donations could have potentially resulted in TTIs in recipients of multiple components derived from each donation.…”

Section: Discussionmentioning

confidence: 99%

International review of blood donation nucleic acid amplification testing

Faddy,

Osiowy,

Custer

et al. 2024

Vox Sanguinis

Self Cite

View full text Add to dashboard Cite

Background and ObjectivesNucleic acid amplification testing (NAT), in blood services context, is used for the detection of viral and parasite nucleic acids to reduce transfusion‐transmitted infections. This project reviewed NAT for screening blood donations globally.Materials and MethodsA survey on NAT usage, developed by the International Society of Blood Transfusion Working Party on Transfusion‐transmitted Infectious Diseases (ISBT WP‐TTID), was distributed through ISBT WP‐TTID members. Data were analysed using descriptive statistics.ResultsForty‐three responses were received from 32 countries. Increased adoption of blood donation viral screening by NAT was observed over the past decade. NAT‐positive donations were detected for all viruses tested in 2019 (proportion of donations positive by NAT were 0.0099% for human immunodeficiency virus [HIV], 0.0063% for hepatitis C virus [HCV], 0.0247% for hepatitis B virus [HBV], 0.0323% for hepatitis E virus [HEV], 0.0014% for West Nile virus [WNV] and 0.00005% for Zika virus [ZIKV]). Globally, over 3100 NAT‐positive donations were identified as NAT yield or solely by NAT in 2019 and over 22,000 since the introduction of NAT, with HBV accounting for over half. NAT‐positivity rate was higher in first‐time donors for all viruses tested except WNV. During 2019, a small number of participants performed NAT for parasites (Trypanosoma cruzi, Babesia spp., Plasmodium spp.).ConclusionThis survey captures current use of blood donation NAT globally. There has been increased NAT usage over the last decade. It is clear that NAT contributes to improving blood transfusion safety globally; however, there is a need to overcome economic barriers for regions/countries not performing NAT.

show abstract

Section: Discussionmentioning

confidence: 99%

International review of blood donation nucleic acid amplification testing

Faddy,

Osiowy,

Custer

et al. 2024

Vox Sanguinis

Self Cite

View full text Add to dashboard Cite

show abstract

“…Bacterial transmission is much more common than well-recognized and documented viral transmission [ 1 , 2 , 3 ]. The U.S. Food and Drug Administration (FDA) registered two to three fatal cases per year, recently [ 1 , 4 ].…”

Section: Bacterial Transmissionmentioning

confidence: 99%

Transfusion-Transmitted Disorders 2023 with Special Attention to Bone Marrow Transplant Patients

et al. 2023

View full text Add to dashboard Cite

Transfusion medicine is traditionally a strong/fundamental part of clinical practice, saving hundreds of millions of lives. However, blood-borne or transmitted infections are a well-known and feared possibility, a risk we relentlessly mitigate. Pathogens are continuously and rather quickly changing, so during the last decade, many, sometimes exotic, new pathogens and diseases were recorded and analyzed, and some of them were proved to be transmitted with transfusions. Blood or blood component transfusions are carried out after cautious preparative screening and inactivation maneuvers, but in some instances, newly recognized agents might escape from standard screening and inactivation procedures. Here, we try to focus on some of these proven or potentially pathogenic transfusion-transmitted agents, especially in immunocompromised patients or bone marrow transplantation settings. These pathogens are sometimes new challenges for preparative procedures, and there is a need for more recent, occasionally advanced, screening and inactivation methods to recognize and eliminate the threat a new or well-known pathogen can pose. Pathogen transmission is probably even more critical in hemophiliacs or bone marrow transplant recipients, who receive plasma-derived factor preparations or blood component transfusions regularly and in large quantities, sometimes in severely immunosuppressed conditions. Moreover, it may not be emphasized enough that transfusions and plasma-derived product administrations are essential to medical care. Therefore, blood-borne transmission needs continued alertness and efforts to attain optimal benefits with minimized hazards.

show abstract

“…In accordance with local epidemiology, WNV-NATs have also been integrated in the blood donation screening strategies of some countries, and most recently, NATs to detect Babesia sp. and Zika virus infections have been implemented in the USA, the latter of which was eventually discontinued [ 12 , 15 , 16 , 17 , 18 ]. Testing strategies have been very effective in reducing risks once identified [ 19 ].…”

Section: Introductionmentioning

confidence: 99%

Emerging Pathogen Threats in Transfusion Medicine: Improving Safety and Confidence with Pathogen Reduction Technologies

et al. 2023

View full text Add to dashboard Cite

Emerging infectious disease threats are becoming more frequent due to various social, political, and geographical pressures, including increased human–animal contact, global trade, transportation, and changing climate conditions. Since blood products for transfusion are derived from donated blood from the general population, emerging agents spread by blood contact or the transfusion of blood products are also a potential risk. Blood transfusions are essential in treating patients with anemia, blood loss, and other medical conditions. However, these lifesaving procedures can contribute to infectious disease transmission, particularly to vulnerable populations. New methods have been implemented on a global basis for the prevention of transfusion transmissions via plasma, platelets, and whole blood products. Implementing proactive pathogen reduction methods may reduce the likelihood of disease transmission via blood transfusions, even for newly emerging agents whose transmissibility and susceptibility are still being evaluated as they emerge. In this review, we consider the Mirasol PRT system for blood safety, which is based on a photochemical method involving riboflavin and UV light. We provide examples of how emerging threats, such as Ebola, SARS-CoV-2, hepatitis E, mpox and other agents, have been evaluated in real time regarding effectiveness of this method in reducing the likelihood of disease transmission via transfusions.

show abstract

Evolution of Blood Safety in Switzerland over the Last 25 Years for HIV, HCV, HBV and Treponema pallidum

Cited by 9 publications

References 39 publications

International review of blood donation nucleic acid amplification testing

International review of blood donation nucleic acid amplification testing

Transfusion-Transmitted Disorders 2023 with Special Attention to Bone Marrow Transplant Patients

Emerging Pathogen Threats in Transfusion Medicine: Improving Safety and Confidence with Pathogen Reduction Technologies

Contact Info

Product

Resources

About